SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 170.71 |
Enterprise Value ($M) | 250.43 |
Book Value ($M) | -92.48 |
Book Value / Share | -1.47 |
Price / Book | -1.85 |
NCAV ($M) | -92.79 |
NCAV / Share | -1.48 |
Price / NCAV | -1.84 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -3.72 |
Return on Assets (ROA) | -2.03 |
Return on Equity (ROE) | n/a |
Liquidity (mrq) | |
---|---|
Quick Ratio | 1.13 |
Current Ratio | 1.13 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 28.67 |
Assets | 28.97 |
Liabilities | 121.45 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | 0.00 |
Net Income | 0.00 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | 0.00 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
49,324 | 124,739 | 39.54 | |
31,645 | 127,643 | 24.79 | |
40,637 | 125,126 | 32.48 | |
37,343 | 102,582 | 36.40 | |
(click for more detail) |
Similar Companies | |
---|---|
FENC – Fennec Pharmaceuticals Inc. | FLGC – Flora Growth Corp. |
FTLF – FitLife Brands, Inc. | GDTC – CytoMed Therapeutics Limited |
GELS – Gelteq Limited |